Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753057 | 0.82 | NLRP3 (0.51) | NLRP3THRBPOLBUBE2NTP53 | |
| SCHEMBL23950818 | 0.79 | NLRP3 (0.62) | NLRP3THRBPOLBUBE2NTP53 | |
| SCHEMBL23950187 | 0.75 | POLB (0.46) | NLRP3THRBPOLBUBE2NKMT2A | |
| SCHEMBL25754628 | 0.75 | NLRP3 (0.50) | NLRP3THRBPOLBUBE2NTP53 | |
| SCHEMBL23950383 | 0.74 | NLRP3 (0.66) | NLRP3THRB | |
| SCHEMBL23950380 | 0.74 | POLB (0.44) | NLRP3THRBPOLBUBE2NTP53 | |
| SCHEMBL23950418 | 0.73 | NLRP3 (0.43) | NLRP3THRBPOLBUBE2NKMT2A | |
| SCHEMBL23950819 | 0.73 | THRB (0.48) | NLRP3THRBPOLBUBE2NTP53 | |
| SCHEMBL23950385 | 0.72 | NLRP3 (0.61) | NLRP3THRBTP53CHRNA1CHRNA3 | |
| SCHEMBL23950842 | 0.72 | NLRP3 (0.45) | NLRP3THRBPOLBUBE2NTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885THRB 2320/4885POLB 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.